关键信息
-
基因名
IGFBP-4
- 应用
-
别名
BP4; HT29-IGFBP; IBP4
-
种属
Rat
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P21744
-
表达区间
Asp22~Glu254
-
蛋白长度
Partial
-
分子量
33&35kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Insulin-like growth factor binding protein 4 (IGFBP-4) is a member of the IGFBP family, which plays a crucial role in the regulation of insulin-like growth factors (IGFs), themselves vital for growth and development in mammals. Research has shown that IGFBP-4 can modulate the availability and activity of IGFs, thus influencing numerous biological processes, including cell proliferation, differentiation, and apoptosis. Elevated levels of IGFBP-4 have been implicated in various pathological conditions, such as cancer, diabetes, and cardiovascular diseases, making it a key target for therapeutic interventions. The production of recombinant IGFBP-4 protein in vitro allows for detailed studies of its structure-function relationships and biological activities. By employing recombinant DNA technology, scientists can generate large quantities of this protein, facilitating investigations into its role in physiological and pathological processes. Understanding the molecular mechanisms underlying IGFBP-4's functions may open new avenues for diagnostic and therapeutic strategies, particularly in diseases where IGF signaling is disrupted. Hence, the study of recombinant IGFBP-4 protein is essential for elucidating its potential as a biomarker and therapeutic target, reinforcing its significance in both clinical and research settings.
